OR WAIT 15 SECS
The UK’s Medicines Discovery Catapult (MDC) and the BioIndustry Association have today released the 2019 State of the Discovery Nation report, providing insights into the UK’s growing medicines discovery industry. Revealing “a thriving service and supply sector for the UK in addition to its R&D biotechs”, the research found that service and supply companies account for 80% of small and medium enterprises (SMEs) in UK medicines discovery, and 90% of employment. Twenty per cent of companies are actively focussed on therapeutic product development. Key insights from the report reveal:
In addition, the BIA’s benchmarking report showed that by 2025 the UK could support an additional:
The report also shows that the medicines discovery community view AI as not only one of the current ‘hot areas’, but integral to improving medicines discovery decision making.
Chris Molloy, Chief Executive Officer of Medicines Discovery Catapult, commented: “It is vital that we maintain our global competitiveness and R&D services can be a major sector driving international trade. The report’s findings help shape our strategy at MDC and we will continue to strengthen R&D productivity to create new medicines for patients.” Steve Bates, Chief Executive Officer of BioIndustry, added: “Many virtual and small biotechs, as well as established global pharma players, rely on the expertise and capability of UK service providers... It’s vitally important policy makers understand this network and supply chain as we work together to deliver the UK life science industrial strategy.” Read the full report at